

Method

CRISPR RNAs trigger innate immune responses in human cells

Sojung Kim,^{1,6} Taeyoung Koo,^{1,2,6} Hyeon-Gun Jee,^{3,6} Hee-Yeon Cho,¹ Gyeorae Lee,^{1,2} Dong-Gyun Lim,³ Hyoung Shik Shin,⁴ and Jin-Soo Kim^{1,2,5}

¹Center for Genome Engineering, Institute for Basic Science, Seoul 08826, South Korea; ²Department of Basic Science, University of Science & Technology, Daejeon 34113, South Korea; ³Center for Chronic Diseases, Research Institute, National Medical Center, Seoul 04564, South Korea; ⁴Research Center for Infectious Diseases, Research Institute, National Medical Center, Seoul 04564, South Korea; ⁵Department of Chemistry, Seoul National University, Seoul 08826, South Korea

Here, we report that CRISPR guide RNAs (gRNAs) with a 5'-triphosphate group (5'-ppp gRNAs) produced via in vitro transcription trigger RNA-sensing innate immune responses in human and murine cells, leading to cytotoxicity. 5'-ppp gRNAs in the cytosol are recognized by DDX58, which in turn activates type I interferon responses, causing up to ~80% cell death. We show that the triphosphate group can be removed by a phosphatase in vitro and that the resulting 5'-hydroxyl gRNAs in complex with Cas9 or Cpf1 avoid innate immune responses and can achieve targeted mutagenesis at a frequency of 95% in primary human CD4⁺ T cells. These results are in line with previous findings that chemically synthesized sgRNAs with a 5'-hydroxyl group are much more efficient than in vitro-transcribed (IVT) sgRNAs in human and other mammalian cells. The phosphatase treatment of IVT sgRNAs is a cost-effective method for making highly active sgRNAs, avoiding innate immune responses in human cells.

[Supplemental material is available for this article.]

Clustered, regularly interspaced, short palindromic repeat (CRISPR)-CRISPR associated (Cas) nucleases, which function as an adaptive immune system in bacteria and archaea, have been repurposed for targeted genome editing in various cells and organisms (Cho et al. 2013a; Kim and Kim 2014). The Cas9 nuclease, the protein component in a type II CRISPR-Cas system, is complexed with two small RNAs termed a target-specific CRISPR RNA (crRNA) (~40 nucleotides [nt] in length) and a target-independent *trans*-activating crRNA (tracrRNA) (~86-nt) to form active RNA-guided endonucleases (Deltcheva et al. 2011; Jinek et al. 2012), which cleave DNA in a targeted manner, leading to site-specific genome modifications. The essential parts of the crRNA and tracrRNA are usually combined to generate a ~100-nt single guide RNA (sgRNA). Cpf1 is another RNA-guided programmable nuclease, which is derived from a class 2 type V CRISPR-Cas system (Zetsche et al. 2015). Unlike Cas9, Cpf1 requires only a single 42-nt crRNA to cleave target DNA.

For successful CRISPR-mediated genome editing, efficient delivery or high level expression of Cas9 or Cpf1 and a guide RNA (gRNA) is essential. Plasmids encoding Cas9 and a gRNA or in vitro-transcribed Cas9 mRNA and a gRNA can be codelivered into cells. As an alternative to these methods, preassembled Cas9 or Cpf1 ribonucleoproteins (RNPs), composed of the purified Cas9 or Cpf1 protein and a gRNA, can be also delivered into cells via microinjection (Cho et al. 2013b; Sung et al. 2014), electroporation (Kim et al. 2014, 2016; Hur et al. 2016), cationic lipid-mediated transfection (Zuris et al. 2015), or protein transduction (Ramakrishna et al. 2014). RNPs cut target DNA immediately and

are turned over rapidly in cells, which can alleviate off-target effects (Kim et al. 2014) and reduce mosaicism in whole organisms (Woo et al. 2015). Unlike plasmid transfection, RNP delivery is not associated with any risk of foreign DNA integration into the host genome (Kim et al. 2014) and cannot trigger cyclic GMP-AMP synthase (cGAS) activation, an innate immune system in mammalian cells that protects against foreign DNA (Sun et al. 2013). This advantage of RNP delivery over plasmid transfection has made Cas9, Cpf1, and Base Editor RNPs broadly useful for biomedical research and biotechnology (Woo et al. 2015; Dever et al. 2016; Kim et al. 2017a,c; Liang et al. 2017).

gRNAs in RNP complexes are typically transcribed in vitro using phage RNA polymerases such as T7 and SP6 polymerases. These in vitro-transcribed (IVT) gRNAs contain a triphosphate group at the 5' terminus, which can induce a type I interferon-mediated immune response in various cell types (Kim et al. 2004; Pichlmair et al. 2006). The nascent 5'-triphosphate moiety in such an RNA molecule is recognized as part of a non-self RNA derived from viral infection. Immune sensing of non-self nucleic acids by innate immune systems leads to the induction of the type I interferons (IFNs), which in turn activate genes that encode antiviral effector proteins such as DDX58 (DEXD/H-box helicase 58, also known as RIG-I), OAS2 (2'-5'-oligoadenylate synthetase), and PKR (dsRNA-dependent protein kinase) (Schlee and Hartmann 2016).

Here, we investigate whether the 5'-triphosphate moiety in IVT gRNAs indeed triggers the RNA-sensing innate immune response in human cells, leading to cell death, and show how to avoid this problem.

[¶]These authors contributed equally to this work.

Corresponding author: jskim01@snu.ac.kr

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.231936.117>. Freely available online through the *Genome Research* Open Access option.

© 2018 Kim et al. This article, published in *Genome Research*, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Results

Activation of type I interferon responses by 5'-triphosphate gRNA

We first tested whether IVT gRNAs (dual RNA [crRNA plus tracrRNA] or sgRNA) could activate innate immune responses in

cultured human cells. *HBB* gene-specific gRNAs were synthesized using T7 polymerase, complexed with the recombinant *Streptococcus pyogenes* Cas9 protein expressed in and purified from *Escherichia coli* and transfected into HeLa cells via lipofection (Fig. 1A). The expression of *IFNB1*, a hallmark of the type I IFN pathway, was evaluated by quantitative PCR and ELISA 24 h after transfection.




Figure 1. Induction of type I interferon-mediated innate immune responses in HeLa cells by in vitro-transcribed gRNA containing 5'-triphosphate. (A) Schematic representation of gRNA 5' ends, which vary according to the gRNA preparation method. gRNA sequences complementary to the *HBB*-target site are shown in bold. (B, D, E) Relative *IFNB1* (B), *DDX58* (D), and *OAS2* (E) mRNA levels 24 h after transfection. Error bars, SEM; $n = 3$. (C) *IFNB1* levels were measured by ELISA. Error bars, SEM; $n = 3$. (N.D.) None detected. (F) Cell viabilities after RNP transfection were determined by WST-1 assays. Error bars, SEM; $n = 2$. Statistical significances between the different measurements were calculated using one-way ANOVA. (***) $P < 0.001$, (****) $P < 0.0001$. (G) Indel frequencies induced by the *HBB*-targeting Cas9 RNP were measured by targeted deep sequencing. Error bars, SEM; $n = 3$. Statistical significances were calculated by *t*-test. (n.s.) Not significant, (Syn) chemically synthesized guide RNA, (IVT) in vitro-transcribed gRNA, (\pm CIP) in vitro-transcribed gRNA with or without CIP treatment.

The Cas9 RNP up-regulated *IFNB1* mRNA levels by ~1000-fold and protein levels by ~200-fold (Fig. 1B,C). The Cas9 protein alone did not activate the IFN pathway, whereas 5'-triphosphorylated (5'-ppp) gRNAs alone activated the expression of *IFNB1*. In sharp contrast, transfection of 5'-hydroxylated (5'-OH) gRNAs, prepared by chemical synthesis or by treatment of IVT gRNAs with calf intestinal phosphatase (CIP), caused no significant difference in *IFNB1* expression compared to that of untreated negative controls. IFN-stimulated *DDX58* and *OAS2* genes were also up-regulated by 5'-ppp gRNAs but not by 5'-OH gRNAs (Fig. 1D,E). Consistent with these results, cytotoxicity, caused by the type I IFN pathway, was observed with 5'-ppp sgRNAs but not with 5'-OH gRNAs (Fig. 1F). Thus, >80% of cells were killed by 5'-ppp sgRNAs. Dual RNAs containing the triphosphate group were also cytotoxic, killing up to 60% of transfected cells.

Next, we measured *HBB* gene editing efficiencies in human cells transfected with 5'-ppp gRNAs or 5'-OH gRNAs (Fig. 1G). Both 5'-OH gRNAs and 5'-ppp gRNAs were equally efficient in HeLa cells, demonstrating that the triphosphate moiety at the 5'-end of sgRNAs does not affect DNA cleavage activity in human cells and suggesting that indels were formed before massive cell death. Note also that 5'-ppp gRNA transfection triggers production and secretion of interferon proteins in the media, which then bind to ubiquitously expressed receptors even in untransfected cells, leading to cell death.

We further investigated whether 5'-ppp-gRNAs trigger RNA-sensing immune responses in primary mouse embryonic fibroblast (MEF) cells (Supplemental Fig. S1A). The *Ifnb1* and IFN-stimulated genes *Ddx58* and *Oas2* were up-regulated in MEF cells transfected with 5'-ppp-sgRNAs generated via in vitro transcription but not in those transfected with 5'-OH-gRNAs prepared by chemical synthesis or CIP treatment of IVT sgRNAs (Supplemental Fig. S1B–D). There was no difference in gene editing efficiencies between 5'-ppp-sgRNA and 5'-OH-sgRNA cotransfected with the Cas9 protein (Supplemental Fig. S1E).

RNA-sensing immune response to CRISPR-RNA via *DDX58*

Cytosolic 5'-triphosphorylated RNAs, the main ligand for the *DDX58* receptor, can function as an indicator of viral infection (Pichlmair et al. 2006; Rehwinkel et al. 2010). Hence, we hypothesized that *DDX58* might be involved as the immune sensor responsible for detection of IVT gRNAs. To verify this, we first generated *DDX58* knockout (KO) cell lines using a *DDX58*-specific sgRNA and Cas9 (Fig. 2A). We chose two KO clones with out-of-frame indel mutations. mRNA levels of *IFNB1*, *DDX58*, and *OAS2*




Figure 2. The type I interferon-mediated immune response triggered by gRNA is associated with *DDX58*. (A) Genotypes of *DDX58* knockout (KO) HeLa cell lines. *DDX58* KO clones #1 and #2 have homozygous out-of-frame mutations at the *DDX58* locus. The target sequence complementary to the sgRNA used for mutagenesis is underlined and the PAM sequence is shown in red. (B–D) Relative *IFNB1* (B), *DDX58* (C), and *OAS2* (D) mRNA levels in wild-type (WT) and *DDX58* KO cell lines at 24 h after transfection. Error bars, SEM; $n = 3$. (E) WT and *DDX58* KO cell viabilities after RNP transfection were determined by WST-1 assays. Error bars, SEM; $n = 3$. Statistical significances among the different measurements were calculated using one-way ANOVA. (**) $P < 0.01$, (****) $P < 0.0001$.

were not changed in these *DDX58* KO cells transfected with 5'-ppp-gRNAs (Fig. 2B–D). Furthermore, IFN-mediated cytotoxicity associated with 5'-ppp-gRNAs was not detectably induced in these cells (Fig. 2E), suggesting that *DDX58* is responsible for the innate immune response to IVT gRNAs with the 5' triphosphate moiety.

Type I interferon response induced by crRNA in Cpf1 RNPs

Next, we investigated whether Cpf1 crRNAs can also activate innate immune responses in human cells. We prepared a *DNMT1*-specific *Acidaminococcus* sp. Cpf1 (AsCpf1) crRNA via chemical synthesis or in vitro transcription using T7 polymerase (Fig. 3A). *IFNB1*, *DDX58*, and *OAS2* mRNA levels were up-regulated by the 5'-ppp crRNA but not by the 5'-OH crRNA prepared by chemical synthesis or by treatment of the in vitro transcript with CIP (Fig. 3B–D). Activation of these IFN-mediated immune responses by the 5'-ppp crRNA was abrogated in *DDX58* KO cells (Fig. 3E–G). Mutation frequencies associated with treatment with RNPs containing the 5'-ppp crRNA or the 5'-OH crRNA were comparable,




Figure 3. RNA-sensing immune responses activated by the AsCpf1-associated crRNA. (A) Schematics of *DNMT1*-targeting crRNAs, which vary according to their preparation methods. crRNA sequences complementary to the *DNMT1*-target site are shown in bold. (B–D) Relative *IFNB1* (B), *DDX58* (C), and *OAS2* (D) mRNA levels at 24 h after transfection. Error bars, SEM; $n = 3$. (E–G) Relative *IFNB1* (E), *DDX58* (F), and *OAS2* (G) mRNA levels in WT and *DDX58* KO HeLa cell lines at 24 h post-transfection. Error bars, SEM; $n = 3$. (H) Indel frequencies induced by the *DNMT1*-targeting AsCpf1 RNP were measured using next-generation sequencing (NGS). Statistical significances were calculated by *t*-test. (n.s.) Not significant, (Syn) chemically synthesized crRNA, (IVT) in vitro-transcribed crRNA, (\pm CIP) in vitro-transcribed crRNA with or without CIP treatment.

showing that the cleavage activity of Cpf1 was not affected by the 5'-triphosphate group of the crRNA (Fig. 3H).

Cytotoxicity induced by 5'-ppp sgRNAs in primary human T cells

Genome editing in primary human T cells has been tested in clinics for treating cancer and human immunodeficiency virus type 1 (HIV-1) infection. We investigated whether 5'-triphosphate sgRNAs trigger innate immune responses in primary human T cells, causing cytotoxicity. We isolated primary CD4⁺ T cells

from healthy volunteers ($n = 3$) and transfected a Cas9 RNP specific to the *CCR5* gene, which encodes an essential coreceptor of HIV-1, into these cells via electroporation. We measured adenosine triphosphate (ATP) levels to monitor cell viability and found that the 5'-ppp gRNA treatment significantly reduced cell viability ($*P < 0.05$, $**P < 0.01$), whereas 5'-OH-sgRNA did not cause cytotoxicity (Fig. 4A). Furthermore, 5'-ppp gRNA-treated cells failed to divide after 7 d post-electroporation, whereas cells transfected with CIP-treated 5'-OH sgRNA in complex with the Cas9 protein were successfully expanded (Fig. 4B).




Figure 4. 5'-triphosphate induces RNA-sensing immune responses in human CD4⁺ T cells. A *CCR5*-targeting Cas9 RNP was delivered into primary CD4⁺ T cells using a MaxCyte electroporation system. (A) Cell viabilities at 3 and 7 d post-electroporation were determined by relative ATP level. (B) Live cell numbers from day 0 to 8 were counted after RNP delivery. Relative *OAS2* (C) and *DDX58* (D) mRNA levels were determined by real-time PCR 3 d post-electroporation. (E) IFNβ1 protein levels in the supernatant were measured by ELISA. Error bars, SEM; $n = 3$. Statistical significances were calculated by *t*-test. (*) $P < 0.05$, (**) $P < 0.01$, (n.s.) not significant.

We next investigated whether the cytotoxicity of 5'-ppp sgRNA in primary CD4⁺ T cells was caused by RNA-sensing innate immune responses. As expected, *OAS2* and *DDX58* mRNA levels were up-regulated by the 5'-triphosphate sgRNA (** $P < 0.01$) (Fig. 4C,D). The IFNβ1 protein was also detected at day 3 post-electroporation (Fig. 4E). The 5'-OH sgRNA did not induce any detectable immune responses, compared to the mock control.

Highly efficient *CCR5* knockout in human T cells using 5'-OH sgRNA

We next measured mutation frequencies in primary T cells using targeted deep sequencing. Removal of the 5'-triphosphate moiety from the sgRNA enhanced mutation efficiencies at the *CCR5* target site in T cells. Thus, the 5'-OH sgRNA induced indels with a frequency of $94 \pm 0.4\%$ and $92 \pm 0.8\%$ at day 3 and 7 post-electroporation, respectively, whereas the 5'-ppp sgRNA induced indels with a frequency of $87 \pm 1\%$ and $80 \pm 1\%$ (** $P < 0.01$) (Fig. 5A). Importantly, 5'-OH sgRNA-treated cells remained mutated at the *CCR5* locus with a frequency of $95 \pm 1\%$ at day 25 post-treatment (Fig. 5B).

To confirm the removal of the *CCR5* protein from the surface of CD4⁺ T cells as a result of CRISPR gene editing, we performed flow cytometry. At day 7 post-electroporation, 96% of cells (both mock-treated and Cas9 RNP-treated) were CD4 positive (Fig. 5C; Supplemental Fig. S2). Among these CD4⁺ T cells, only 3.7% of cells treated with the Cas9 RNP were *CCR5*-positive, whereas 24.4% of mock-treated cells were *CCR5*-positive, showing an 85% reduction in the fraction of *CCR5*-positive cells upon Cas9 RNP treatment (Fig. 5D; Supplemental Fig. S2).

Discussion

The delivery of CRISPR RNP complexes that consist of Cas9 or Cpf1 protein and guide RNA into mammalian (Kim et al. 2014, 2016; Hur et al. 2016) and plant cells (Woo et al. 2015) and animal (Cho et al. 2013b; Sung et al. 2014) and human embryos (Ma et al. 2017) has been demonstrated as a promising approach for highly efficient and precise genome editing. CRISPR RNPs have been successfully delivered into retinal pigment epithelium cells (Kim et al. 2017b), neuronal cells (Stahl et al. 2017), and hair cells (Zuris et al. 2015) in mice, illustrating the broad potential for clinical applications. To prepare gRNAs for RNP delivery, in vitro transcription using phage RNA polymerases, such as T7 and SP6 polymerases, is the most accessible method because it is easier and more affordable than chemical synthesis for obtaining large amounts of RNA. In particular, the yield of ~100-nt sgRNAs from chemical

synthesis is very low (Hendel et al. 2015), and thus preparation of sgRNAs in amounts sufficient for transfecting $10^7 \sim 10^9$ cells by this method can be cost-prohibitive. However, in vitro transcription using phage RNA polymerases generates a triphosphate moiety at the 5' end of the gRNA, and the resulting 5'-triphosphate single-stranded RNA (ssRNA) activates type I interferon-mediated immune responses in cells. Cytosolic ssRNAs bearing 5'-triphosphates are recognized by the DDX58 receptor (Pichlmair et al. 2006; Rehwinkel et al. 2010), but the preference of DDX58 for ssRNA ligands varies according to their concentration, sequence, length, conformation, and the level of shielding by proteins (Schlee and Hartmann 2016), and thus the minimal requirement of a biologically relevant ssRNA ligand for DDX58 activity has remained unclear. Here, we demonstrated that in vitro-transcribed gRNAs in CRISPR-Cas9 or Cpf1 RNPs indeed trigger RNA-sensing innate immune responses and result in cell death, which can be prevented by removal of the 5'-triphosphate group from the gRNA.

Human T cells can be gene-edited using CRISPR systems or other programmable nucleases for the treatment of various diseases, including cancer and acquired immune deficiency syndrome (AIDS). For example, a naturally occurring deletion in the *CCR5*




Figure 5. Removing the 5'-triphosphate moiety from gRNA improves *CCR5* editing efficiency in primary human CD4⁺ T cells. (A) Indel frequencies at the *CCR5* locus were calculated by targeted deep sequencing on day 3 and day 7 post-treatment. (B) Indel frequencies at the *CCR5* locus were calculated by targeted deep sequencing on day 25 post-treatment. The percentages of cells positive for surface CD4 (C) and *CCR5* protein (D) were determined by flow cytometry. Error bars, SEM; $n = 3$. Statistical significances were calculated by *t*-test. (*) $P < 0.05$, (**) $P < 0.01$, (n.s.) not significant.

gene encoding an essential coreceptor of HIV confers resistance to HIV infection, providing the basis of cell therapy against HIV infection (Hendel et al. 2015; Hultquist et al. 2016; Xu et al. 2017). Here, we showed that delivery of RNP complexes containing gRNAs lacking the 5'-triphosphate rescued human CD4⁺ primary T cells from RNA-sensing innate immune responses, leading to efficient disruption of the *CCR5* gene. Application of this strategy offers great promise for targeted cell therapy using CRISPR-Cas9, Cpf1, and Base Editor RNP complexes.

Methods

Preparation of recombinant Cas9 protein, Cpf1 protein, and guide RNA

Recombinant Cas9 protein was purchased from ToolGen. Recombinant Cpf1 protein was prepared as described previously (Hur et al. 2016). Cas9 crRNAs, tracrRNAs, and sgRNAs and Cpf1 crRNAs were synthesized by in vitro transcription using T7 RNA polymerase and a template oligonucleotide (Supplemental Table S1) as described previously (Kim et al. 2014, 2016). CIP (New England BioLabs) was used to remove the 5'-triphosphate from gRNAs as follows: 10 μ g of in vitro-transcribed RNA was treated with 250 units of CIP for 3 h at 37°C in the presence of 100 units

of RNase inhibitor (New England BioLabs). Following CIP treatment, the RNA was cleaned up using a miRNeasy Mini kit (Qiagen). Chemically synthesized RNAs, which were purified using high-performance liquid chromatography (HPLC), were purchased from Integrated DNA Technologies (IDT).

Cell culture and transfection

HeLa (ATCC, CCL-2) cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 100 units/mL penicillin, 100 μ g/mL streptomycin, 0.1 mM nonessential amino acids, and 10% fetal bovine serum (FBS). Mouse embryonic fibroblast cells were grown in DMEM with 20% fetal bovine serum. HeLa cells and MEF cells were transfected with 100 nM of purified Cas9 protein or Cpf1 protein and 300 nM of gRNA using Lipofectamine 2000 reagent (Invitrogen), as described in Zuris et al. (2015).

Isolation of primary human CD4⁺ T cells

Peripheral blood was collected from healthy donors at the National Medical Center of Korea after informed consent with Institutional Review Board approval. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque solution (GE Healthcare). Using a magnetic activated cell sorting (MACS) CD4⁺ T cell isolation kit (Miltenyi Biotec), CD4⁺ T cells were purified by negative selection. Isolated CD4⁺ T cells were cultured in RPMI 1640 medium supplemented with 2 mM glutamine, 1% (v/v) nonessential amino acids, 1% (v/v) sodium pyruvate, 1% (v/v) HEPES, penicillin (50 U/mL), streptomycin (50 μ g/mL), and 10% (v/v) FBS (medium and culture supplements from Invitrogen). Within 2 h of isolation, CD4⁺ T cells were activated with CD3/CD28 Dynabeads (Thermo Fisher Scientific). The CD3/CD28 beads were magnetically removed 72 h after activation, before delivery of RNPs for *CCR5* knockout. For long-term expansion of CD4⁺ T cells, CD3/CD28 Dynabeads were added at 1:1 ratio (cell to bead) again at day 8 post-electroporation (day 11 post-initial activation) (Levine et al. 1997).

RNP delivery into primary human CD4⁺ T cells

RNPs were delivered into T cells via electroporation. Bead-free activated CD4⁺ T cells were mixed with purified Cas9 protein and sgRNA complexes in MaxCyte buffer and transferred into an OC-100 processing assembly, followed by electroporation using a MaxCyte-STX transfection system (MaxCyte Systems) according to the manufacturer's instructions. After electroporation, cells were seeded on 96-well plates with 20 units/mL of recombinant human IL2.

Targeted deep sequencing for mutation detection

Genomic DNA was harvested with a DNeasy Blood & Tissue kit (Qiagen) after RNP transfection. The target regions were PCR-amplified using appropriate primer sets (Supplemental Table S1) for next-generation sequencing library construction. TruSeq HT Dual Index primers were used for labeling each sample. The resulting libraries were subjected to paired-end read sequencing using MiSeq (Illumina).

Measurement of relative mRNA levels by quantitative PCR

Transfected cells were lysed and mRNA was purified either 24 h or 3 d after transfection using a NucleoSpin RNA kit (MACHERY-NAGEL). cDNAs were synthesized by reverse transcription using a miScript II RT kit (Qiagen) and quantified by qPCR using the primers listed in Supplemental Table S1. The qPCR in primary

human CD4⁺ T cells was performed using TaqMan gene expression assays (Thermo Fisher Scientific) with the following primers: *DDX58* (Hs01061436_m1), *OAS2* (Hs00942643_m1), *18SrRNA* (Hs03928990_g1).

ELISA

The amount of IFN β 1 secreted into the growth medium was determined using a Human IFN beta ELISA kit (PBL Assay Science). The medium from RNP-transfected cells was collected at either 24 h or 3 d post-transfection. The IFN β 1 concentration was measured according to the manufacturer's protocol.

Cell viability measurements

In the case of HeLa cells, 5×10^3 of either wild-type or *DDX58* KO cells were plated in 96-well plates 1 d before RNP transfection. At day 3 after transfection, cell viability was determined by a WST-1 assay (Roche) according to the manufacturer's protocol. In the case of primary CD4⁺ T cells, they were plated in 96-well plates after electroporation to deliver RNPs. At day 3 and 7 after electroporation, the ATP level in the supernatants, a measure of cell viability, was determined using the CellTiter-Glo substrate (Promega).

Data access

The deep sequencing data from this study have been submitted to the NCBI Sequence Read Archive (SRA; <https://www.ncbi.nlm.nih.gov/sra>) under accession numbers SRP121089 and SRP129873.

Acknowledgments

This work was supported by a grant from the Institute for Basic Science (IBS-R021-D1).

References

Cho SW, Kim S, Kim JM, Kim JS. 2013a. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat Biotechnol* **31**: 230–232.

Cho SW, Lee J, Carroll D, Kim JS, Lee J. 2013b. Heritable gene knockout in *Caenorhabditis elegans* by direct injection of Cas9–sgRNA ribonucleoproteins. *Genetics* **195**: 1177–1180.

Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* **471**: 602–607.

Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, et al. 2016. CRISPR/Cas9 β -globin gene targeting in human haematopoietic stem cells. *Nature* **539**: 384–389.

Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, et al. 2015. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nat Biotechnol* **33**: 985–989.

Hultquist JF, Schumann K, Woo JM, Manganaro L, McGregor MJ, Doudna J, Simon V, Krogan NJ, Marson A. 2016. A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells. *Cell Rep* **17**: 1438–1452.

Hur JK, Kim K, Been KW, Baek G, Ye S, Hur JW, Ryu SM, Lee YS, Kim JS. 2016. Targeted mutagenesis in mice by electroporation of Cpf1 ribonucleoproteins. *Nat Biotechnol* **34**: 807–808.

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**: 816–821.

Kim H, Kim JS. 2014. A guide to genome engineering with programmable nucleases. *Nat Rev Genet* **15**: 321–334.

Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ. 2004. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. *Nat Biotechnol* **22**: 321–325.

Kim S, Kim D, Cho SW, Kim J, Kim JS. 2014. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res* **24**: 1012–1019.

Kim D, Kim J, Hur JK, Been KW, Yoon SH, Kim JS. 2016. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. *Nat Biotechnol* **34**: 863–868.

Kim H, Kim ST, Ryu J, Kang BC, Kim JS, Kim SG. 2017a. CRISPR/Cpf1-mediated DNA-free plant genome editing. *Nat Commun* **8**: 14406.

Kim K, Park SW, Kim JH, Lee SH, Kim D, Koo T, Kim KE, Kim JH, Kim JS. 2017b. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. *Genome Res* **27**: 419–426.

Kim K, Ryu SM, Kim ST, Baek G, Kim D, Lim K, Chung E, Kim S, Kim JS. 2017c. Highly efficient RNA-guided base editing in mouse embryos. *Nat Biotechnol* **35**: 435–437.

Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH. 1997. Effects of CD28 costimulation on long-term proliferation of CD4⁺ T cells in the absence of exogenous feeder cells. *J Immunol* **159**: 5921–5930.

Liang Z, Chen K, Li T, Zhang Y, Wang Y, Zhao Q, Liu J, Zhang H, Liu C, Ran Y, et al. 2017. Efficient DNA-free genome editing of bread wheat using CRISPR/Cas9 ribonucleoprotein complexes. *Nat Commun* **8**: 14261.

Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, Koski A, Ji D, Hayama T, Ahmed R, et al. 2017. Correction of a pathogenic gene mutation in human embryos. *Nature* **548**: 413–419.

Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e Sousa C. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**: 997–1001.

Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee SK, Kim H. 2014. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. *Genome Res* **24**: 1020–1027.

Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, Robb N, Vreede F, Barclay W, Fodor E, et al. 2010. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. *Cell* **140**: 397–408.

Schlee M, Hartmann G. 2016. Discriminating self from non-self in nucleic acid sensing. *Nat Rev Immunol* **16**: 566–580.

Stahl BT, Benekareddy M, Coulon-Bainier C, Banfal AA, Floor SN, Sabo JK, Urnes C, Munares GA, Ghosh A, Doudna JA. 2017. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. *Nat Biotechnol* **35**: 431–434.

Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* **339**: 786–791.

Sung YH, Kim JM, Kim HT, Lee J, Jeon J, Jin Y, Choi JH, Ban YH, Ha SJ, Kim CH, et al. 2014. Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases. *Genome Res* **24**: 125–131.

Woo JW, Kim J, Kwon SI, Corvalan C, Cho SW, Kim H, Kim SG, Kim ST, Choe S, Kim JS. 2015. DNA-free genome editing in plants with preassembled CRISPR-Cas9 ribonucleoproteins. *Nat Biotechnol* **33**: 1162–1164.

Xu L, Yang H, Gao Y, Chen Z, Xie L, Liu Y, Liu Y, Wang X, Li H, Lai W, et al. 2017. CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. *Mol Ther* **25**: 1782–1789.

Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, et al. 2015. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* **163**: 759–771.

Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen ZY, Liu DR. 2015. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing *in vitro* and *in vivo*. *Nat Biotechnol* **33**: 73–80.

Received November 2, 2017; accepted in revised form January 15, 2018.



CRISPR RNAs trigger innate immune responses in human cells

Sojung Kim, Taeyoung Koo, Hyeon-Gun Jee, et al.

Genome Res. 2018 28: 367-373 originally published online February 22, 2018
Access the most recent version at doi:[10.1101/gr.231936.117](https://doi.org/10.1101/gr.231936.117)

Supplemental Material

<http://genome.cshlp.org/content/suppl/2018/02/15/gr.231936.117.DC1>

References

This article cites 29 articles, 9 of which can be accessed free at:
<http://genome.cshlp.org/content/28/3/367.full.html#ref-list-1>

Open Access

Freely available online through the *Genome Research* Open Access option.

Creative Commons License

This article, published in *Genome Research*, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

An advertisement banner for ThruPLEX HV. The text "ThruPLEX® HV" is in large white font on a dark blue background, with "failproof DNA-seq of FFPE & cfDNA" below it. On the right, the Takara logo is shown, featuring a stylized 'T' and 'K' in a circle, with the word "Takara" and "Contech Wako cellartis" below it.

To subscribe to *Genome Research* go to:
<http://genome.cshlp.org/subscriptions>
